Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

All Issues

Q&A column

NOVEMBER 2024 Q. Our laboratory was cited for a deficiency because the manufacturer and methodology of our tumor marker assay was not available to clinicians. What is the reasoning behind this requirement? Read answer.
Q. For patients who have a hematocrit level greater than 55 percent, is it okay to use a CBC (hematocrit) that was not collected at the same time as the citrate sample? For example, can we use a CBC collected within 24 hours for an inpatient and a CBC from a previous visit for an outpatient? Read answer.

Newsbytes

November 2024—A picture may be worth a thousand words, but a conventional two-dimensional photograph of a surgical specimen can convey only so much information to a pathologist or surgeon. Overall geometry and margin status are difficult to interpret from static, single-perspective images.

Put It on the Board

November 2024—The College of American Pathologists on Oct. 7 filed an amicus brief in support of the plaintiffs in the consolidated cases American Clinical Laboratory Association, et al., v. U.S. Food and Drug Administration, et al., and Association for Molecular Pathology, et al., v. U.S. Food and Drug Administration, et al. Plaintiffs in these consolidated cases challenge a final rule setting out the FDA’s plan to regulate LDTs as medical devices under the Federal Food, Drug and Cosmetic Act. “The Final Rule imposes draconian new restrictions—and crushing compliance costs—on the development and use of LDTs,” the CAP says in its amicus brief.

Letters

November 2024—In “Lab test use: what 1 billion claims tell us” (August issue, page 1), you detailed the conclusions of a research study that analyzed insurance claims from effectively the entire U.S. adult population. The study found what it had sought, that 14.4 million individuals tested had undergone excessive laboratory testing, which is low-value care that poses patient risks and wastes resources. In reviewing the study data and analyses, I found that the methodology did not accurately estimate overuse and that the study overlooked the conclusion the data was screaming for: We are screening far too few people for chronic diseases and need to invest in access to care.

Harm or help? Maternal AFP race adjustments

October 2024—Using a race adjustment in maternal serum alpha-fetoprotein screening has physicians sitting on the fence these days. Including race in calculating risk for open neural tube defects has been a longstanding practice in medicine. Adjusting for higher rates of AFP levels seen in Black pregnant patients, proponents say, allows this population to receive equitable care. That premise lies on one side of the fence. On the other are those who maintain the practice is suspect, even harmful, and that the routine use of a race-based adjustment should stop. With the experience of dropping raced-based adjustments to estimated glomerular filtration rates still fresh in many minds, physicians are now deciding whether to keep or drop the adjustment for maternal serum AFP, even ahead of any potential changes to guidance by groups such as the CAP. Little wonder. Because as anyone who has ever sat on a fence knows, it can easily become a shaky, even painful, perch.

 

New system for hemolysis detection at point of care

October 2024—Werfen launched in July its Gem Premier 7000 with iQM3 blood gas testing system that for the first time makes hemolysis detection possible at the point of care. “Not having the capability to detect hemolysis at the point of care has been a gap in the field for quite a long time,” says Heather Stieglitz, PhD, D(ABCC).

For machine learning model use, turn to checklists

October 2024—Machine learning applications in molecular oncology testing are largely in the research or early clinical implementation phase, though some ML methods have been part of bioinformatics tasks for years, such as variant effect prediction.

Cyber safety and Epic installs: processes and problems

October 2024—Instrument assessments for cyber safety are in need of a fast track—or another solution to the delays they’re creating, say some Compass Group laboratory leaders. They met online on Sept. 3 with CAP TODAY publisher Bob McGonnagle, with whom they also talked about mergers and acquisitions and Epic Beaker transitions.

Large B-cell lymphoma with IRF4 rearrangement of retroperitoneal lymph node in an elderly male with concomitant high-grade B-cell lymphoma without IRF4r masquerading as a gastric ulcer

October 2024—CAP TODAY and the Association for Molecular Pathology have teamed up to bring molecular case reports to CAP TODAY readers. AMP members write the reports using clinical cases from their own practices that show molecular testing’s important role in diagnosis, prognosis, and treatment. The following report comes from Henry Ford Health. If you would like to submit a case report, please send an email to the AMP at amp@amp.org. For more information about the AMP and all previously published case reports, visit www.amp.org.

MARKETPLACE

TRENDING